IAS 38.21 Recognition — Core Rule
Under IAS 38.21 Recognition Criteria, an intangible asset is recognised on the balance sheet only when it is probable that future economic benefits attributable to the asset will flow to the entity and the cost of the asset can be measured reliably.
How IAS 38.21 Recognition Works
IAS 38 establishes a two-part recognition test alongside the overarching definition of an intangible asset. All three definitional characteristics — identifiability, control, and future economic benefits — must be satisfied before applying the recognition criteria at IAS 38.21.
- Identifiability (IAS 38.11–12): An asset is identifiable if it is separable (can be sold, transferred, licensed, or rented separately) or arises from contractual or legal rights, regardless of whether those rights are transferable. This distinguishes intangible assets from internally generated goodwill, which is never recognised (IAS 38.48).
- Control (IAS 38.13–16): The entity must have the power to obtain future economic benefits from the underlying resource and restrict others' access to those benefits. Control typically arises from legal rights (patents, copyrights); however, skilled staff and customer relationships usually fail this test unless backed by legal enforceability (IAS 38.15).
- Future economic benefits — probability (IAS 38.21(a)): The probability assessment must use reasonable and supportable assumptions representing management's best estimate of the economic environment over the asset's useful life. For separately acquired intangibles, the probability criterion is always considered satisfied (IAS 38.25), reflecting that a market transaction inherently validates expected inflows.
- Reliable measurement of cost (IAS 38.21(b)): Cost must be determinable with sufficient reliability. For separately acquired assets, purchase price plus directly attributable costs (IAS 38.27) form the cost base. For internally generated intangibles, only costs incurred during the development phase (IAS 38.57) qualify; research-phase expenditure is expensed as incurred (IAS 38.54).
- The six-criteria development phase test (IAS 38.57): Capitalisation of development costs requires demonstration of: (1) technical feasibility, (2) intention to complete, (3) ability to use or sell, (4) probable future economic benefits, (5) adequate resources to complete, and (6) ability to reliably measure expenditure attributable to the intangible. All six must be met simultaneously.
- Disclosure of judgement (IAS 38.118–128): Entities must disclose useful lives, amortisation methods, carrying amounts, and any indication of impairment for each class of intangible. Judgements around the probability of future economic benefits and development cost capitalisation are particularly scrutinised by auditors.
IAS 38.21 Recognition — Practical Example
Scenario: A pharmaceutical company incurs €2,000,000 in research costs and subsequently €1,500,000 in development costs on a new drug compound. At the point development begins, all six IAS 38.57 criteria are demonstrably met. A separately acquired patent is also purchased for €500,000 (including legal fees of €20,000).
Research phase — expensed immediately (IAS 38.54)
| Account | Dr (€) | Cr (€) |
|---|
| R&D Expense (P&L) | 2,000,000 | |
| Cash / Accruals | | 2,000,000 |
Development phase — capitalised (IAS 38.57)
| Account | Dr (€) | Cr (€) |
|---|
| Intangible Asset — Development Costs | 1,500,000 | |
| Cash / Accruals | | 1,500,000 |
Separately acquired patent (IAS 38.27)
| Account | Dr (€) | Cr (€) |
|---|
| Intangible Asset — Patent | 520,000 | |
| Cash | | 520,000 |
The patent's cost includes the €20,000 legal fee as a directly attributable cost under IAS 38.27. The €1,500,000 development asset will be amortised over its useful life once the drug is available for use (IAS 38.97).
IAS 38.21 Recognition — Common Pitfalls
- Premature capitalisation of research costs: Teams frequently conflate early-stage feasibility studies with development activities. Unless the entity can clearly delineate the research/development boundary and evidence all six IAS 38.57 criteria, costs must be expensed. Reclassifying previously expensed research to an asset is prohibited (IAS 38.71).
- Misapplying the probability test to business-combination intangibles: Under IFRS 3.B31, intangible assets acquired in a business combination are recognised separately from goodwill even if the probability criterion would otherwise not be met — the fair value measurement subsumes the probability assessment. Applying IAS 38.21 directly here leads to under-recognition.
- Capitalising internally generated brands, mastheads, and customer lists (IAS 38.63): These are explicitly prohibited from recognition regardless of development expenditure incurred, because their cost cannot be distinguished from the cost of developing the business as a whole. Auditors regularly challenge marketing expenditure that has been improperly deferred.
IAS 38.21 Recognition — Key Paragraphs
- IAS 38.21 — the two-part recognition criteria (probable future economic benefits + reliable cost measurement)
- IAS 38.54 & 38.57 — research costs expensed vs. development costs capitalised (six-criteria test)
- IAS 38.25 — probability deemed satisfied for separately acquired intangibles
- IAS 38.48 & 38.63 — prohibition on recognising internally generated goodwill, brands, and customer lists
- IAS 38.27 — measurement of cost for separately acquired intangible assets
